A New Era of Innovation and Patient Care

Dr. Peter Fitzgerald is Director of the Center for Cardiovascular Technology at Stanford University Medical School, and Co-founder/Managing Partner at Triventures. He is an Interventional Cardiologist and has a PhD in Engineering.  He is Professor Emeritus in the Departments of Medicine and Engineering at Stanford.   He has led or participated in over 150 clinical trials, published over 450 manuscripts/chapters, and lectures worldwide.  Peter has been principle/founder of 24 healthcare companies in Silicon Valley, has transitioned 18 of these start-ups to medium/large-cap life science companies and remains on several of their advisory boards.  He has been a consultant for the FDA for the past 15 years focused on medical technology and more recently, digital health.   Prior, Peter was a co-founding partner of LVP capital in San Francisco, deriving his experience in venture capital from three funds focused on medical device and biotechnology start-ups. Peter is co-founder and managing partner of Triventures and heads the US office.   Peter currently participates on the boards of: Cala Health, Cathworks, Day Zero Diagnostics, FemSelect, Genoox, HealthReveal, V-wave.   Past Triventures’ portfolio companies where Peter participated on the boards include: Apica, MST, Orthospace and Zingbox.

Dr. Haders has 20+ years of experience in healthcare as a scientist, entrepreneur, advisor & investor. Dr. Haders is currently the Co-Founder and CEO of Model Medicines, a PIND stage AI/ML Drug Discovery company that has built a pipeline of novel acting broad-spectrum antiviral, oncology and GI assets (https://www.modelmedicines.com/pipeline), including the potential best-in-class, first-in-class MDL-001. More information about MDL-001 and the oncology program can be found here (https://www.modelmedicines.com/newsroom). Model Medicines has raised over $8M to date with backing from investors including 8VC, Friedman Bioventures, Irving Ventures and ParticleX. Prior to co-founding Model Medicines, Daniel launched the Nex Cubed Digital Health Accelerator. Here, Daniel built an early-stage investment portfolio of 25+ Digital Healthcare companies with an enterprise value of over $250M, investment results that would place the portfolio in the top decile. The accelerator has been named one of the Top Ten Global Digital Health Accelerators and The Best Accelerators & Incubators for FemTech Startups. He is also an Operating Partner at Sway Ventures, leading Digital Health investing and portfolio oversight. Dr. Haders is a Board Observer at AppliedVR, a VR digital therapeutic company, backed by investors including F-Prime, Jazz, SVB, JJDC and Sway, which was granted break though device designation and cleared by the FDA in 2022. Other investments include MedCrypt, which recently closed its Series B with co-investors including Dexcom, JJDC, Intuitive Ventures, and Section 32 among others. Dr. Haders is a Faculty Member and Member of the Advisory Committee of the UCSD, Digital Health Certificate Program and a Member of the BioMedX Oversight Committee at Columbia University Technology Ventures. Prior to his current roles, Dr. Haders held positions from research fellow to senior scientist to Co-Founder/CEO in the fields of medical devices, pharmaceuticals & nano-drug delivery. At LuxBio, Daniel and Model Medicines Co-Founder Sean Russell helped develop LX214 from concept through a successful Phase I study. The LX214 program/formulation was further developed clinically by Sun Pharma & gained FDA approval under the name CEQUA in 2018. Dr. Haders holds both a BS and PhD in Biomedical Engineering and has been awarded multiple Fellowships for scientific research including a National Science Foundation IGERT Fellowship in Integratively Engineered Biointerfaces and a Department of Education GAANN Fellowship in Molecular, Cellular and Nanosystems Bioengineering.

Ms. Longmore-Grund is a global "C" level executive with deep strategic, operational and financial leadership experience across a variety of company profiles ranging from public and private Fortune 100, mid cap, PE and venture-funded startups. She has significant capital markets experience, leading 30+ transformational M&A and capital formation transactions with ~ $3.5B of value and building high performing leadership teams who successfully deliver sustainable growth and shareholder value. Ms. Longmore-Grund served as President, Chief Executive Officer and Director of Alliance HealthCare Services from 2018 to 2021. When Alliance was acquired in September of 2021 by Akumin Inc. (NASDAQ: AKU), Ms. Longmore-Grund served as President and Co-CEO as well as Director of the newly merged Akumin company to facilitate a smooth transition and integration through March of 2022. With the acquisition of Alliance HealthCare Services, Akumin became the leading provider of comprehensive radiology and oncology healthcare services, operating ~200 fixed site outpatient imaging and radiation therapy centers, providing outsourced services to over 1,000 hospital partners and locations across 46 states and caring for approximately 2M patients per year. Prior to serving as CEO, Ms. Longmore-Grund served in a variety of financial executive roles. She served as Executive Vice President & Chief Financial Officer of Alliance HealthCare Services (NASDAQ: AIQ), Senior Vice President and Chief Financial Officer for Printronix, a global provider of industrial print technology solutions serving Fortune 500 customers across 100 countries in mission critical manufacturing and supply chain applications. She has also served as the Chief Financial Officer of Velocium, now a Northrop Grumman company.